Pharmacological Characterization of Sigma Binding Sites in Guinea Pig Brain Membranes

  • E. W. Karbon
  • S. J. Enna
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 287)


The pharmacological, biochemical and behavioral characterization of sigma binding sites is currently the focus of intense investigation. First described by Martin and his colleagues (1976) to account for the behavioral effects of selected benzomorphan opiates, sigma binding sites were originally classified as an opioid receptor subtype. Subsequent work suggested this designation was inaccurate since, unlike opioid receptors, the sigma site is insensitive to blockade by naloxone (Itzhak et al., 1985; Katz et al., 1985). In addition, the (+) isomers of opiates such as pentazocine and N-allylnormetazocine (SKF 10,047) are more active at sigma binding sites, while opiate receptors are typically more responsive to (-) isomers (Weber et al., 1986).


Sigma Receptor Haloperidol Administration Sigma Ligand Opioid Receptor Subtype Sigma Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bowen, W.D., DeCosta, B., Hellewell, S.B., Thurkauf, A., Rice, K.C. and Walker, J.M., 1989, Characterization of [3H] (+)-pentazocine, a highly selective sigma ligand, Soc. Neurosci. Abstr., 15:984.Google Scholar
  2. Bowen, W.D., Kirschner, B.N., Newman, A.H. and Rice, K.C., 1988, Sigma receptors negatively modulate agonist-stimulated phosphoinositide metabolism in rat brain, Eur. J. Pharmacol., 149:399–400.PubMedCrossRefGoogle Scholar
  3. Carter, C., Benavides, J., Legendre, P., Vincent, J.D., Noel, F., Thuret, F., Lloyd, K.G., Arbilla, S., Zivkovic, B., Mackenzie, E.T., Scatton, B. and Langer, S.Z., 1988, Ifenprofil and SL 82,0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-Daspartate receptor antagonist properties, J. Pharmacol. Exper. Ther., 247: 1222–1232.Google Scholar
  4. Chouinard, G. and Annable, L., 1984, An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients, Psychopharmacol., 84:282–284.CrossRefGoogle Scholar
  5. Ferkany, J.W., Borosky, S.A., Clissold, D.B. and Pontecorvo, M.J., 1988, Dextromethorphan inhibits NMDA-induced convulsions, Eur. J. Pharmacol., 151:151–154.PubMedCrossRefGoogle Scholar
  6. Goldberg, M., Pham, P. and Choi, D., 1987, Dextrorphan and dextromethorphan block anoxic neuronal injury in culture, Neurology (suppl. 1), 37:250.Google Scholar
  7. Holtzman, S.G., 1985, Discriminative stimulus properties of opioids that interact with mu, kappa and PCP/sigma receptors, in: “Behavioral Pharmacology: The Current Status,” L.S. Seiden and R.L. Balster, eds., Alan R. Liss, Inc., New York.Google Scholar
  8. Itzhak, Y. and Alerhand, S., 1989, Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice, FASEB J., 3:1868–1872.PubMedGoogle Scholar
  9. Itzhak, Y., Hiller, J.M. and Simon, E.J., 1985, Characterization of specific binding sites for [3H] (d)-N-allylnormetazocine in rat brain membranes, Mol. Pharmacol., 27:46–52.PubMedGoogle Scholar
  10. Jenner, P. and Marsden, C.D., 1983, Neuroleptics and tardive dyskinesia, in: “Neurolpetics: Neurochemical, Behavioral, and Clinical Perspectives,” J.T. Coyle and S.J. Enna, eds., Raven Press, New York.Google Scholar
  11. Karbon, E.W., Patch, R.J., Pontecorvo, M.J. and Ferkany, J.W., 1990, Ifenprodil potently interacts with [3H] (+)-3-PPP labeled sigma binding sites in guinea pig brain membranes, Eur. J. Pharmacol., in press.Google Scholar
  12. Karbon, E.W. and Naper, K., 1990, Chronic haloperidol administration differentially regulates [3H] DTG and [3H] (+)-3-PPP labeled sigma binding sites in guinea pig brain membranes. manuscript in preparation.Google Scholar
  13. Katz, J.L., Spealman, R.D. and Clark, R.D., 1985, Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys, J. Pharmacol. Exper. Ther., 232:452–461.Google Scholar
  14. Khansari, N., Whitten, H.D. and Fudenberg, H.H., 1985, Phencyclidine-induced immunodepression, Science, 225:76–78.CrossRefGoogle Scholar
  15. Largent, B.L., Gundlach, A.L. and Snyder, S.H., 1986, Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]-SKF 10,047, (+) -[3H]-3-[3-hydroxyphenyl]-N-(l-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine, J. Pharmacol. Exper. Ther., 238:739–748.Google Scholar
  16. Loo, P., Braunwalder, A., Lehmann, J. and Williams, M., 1986, Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists, Eur. J. Pharmacol., 123:467–468.PubMedCrossRefGoogle Scholar
  17. Maggi, A. and Perez, J., 1985, Role of female gonadal hormones in the CNS: clinical and experimental aspects, Life Sci., 37:893–906.PubMedCrossRefGoogle Scholar
  18. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E. and Gilbert, P.E., 1976, The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol. Exper. Ther., 197:517–532.Google Scholar
  19. Mendelsohn, L.G., Kalra, V., Johnson, B.G. and Kerchner, G.A., 1985, Sigma opioid receptor: characterization and coidentity with the phencyclidine receptor, J. Pharmacol. Exper. Ther., 233:597–602.Google Scholar
  20. Musacchio, J.M., Klein, M. and Santiago, L.J., 1988, High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions, J. Pharmacol. Exper. Ther., 247:424–431.Google Scholar
  21. Musacchio, J.M., Klein, M. and Paturzo, J.J., 1989, Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+) -[3H]3-(-3-hydroxyphenyl)-N-(l-propyl)piperidine, Mol. Pharmacol., 35:1–5.PubMedGoogle Scholar
  22. Naper, K., Pontecorvo, M.J. and Karbon, E.W. 1989, Dextromethorphan distinguishes between [3H] DTG and [3H] (+)-3-PPP labeled sigma receptor binding sites in guinea pig brain membranes, Soc. Neurosci. Abstr., 15:1236.Google Scholar
  23. Prince, D.A. and Feeser, H.R., 1988, Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia, Neurosci. Lett.. 85:291–296.PubMedCrossRefGoogle Scholar
  24. Schoemaker, H., Allen, J. and Langer, S.Z., 1989, Ifenprodil, a novel NMDA antagonist, binds to a polyamine-sensitive site. Soc. Neurosci. Abstr., 15:200.Google Scholar
  25. Shannon, H.E., 1982, Phencyclidine-like discriminative properties of (+)-and (-)-N-allylnormetazocine in rats, Eur. J. Pharmacol., 84:225– 228.PubMedCrossRefGoogle Scholar
  26. Snyder, S.H. and Largent, B.L., 1989, Receptor mechanisms in antipsychotic drug action: focus on sigma receptors, J. Neuropsychiatry. 1:7–15.Google Scholar
  27. Steinfels, G.F., Alberici, G.P., Tam, S.W. and Cook, L., 1988, Biochemical, behavioral and electrophysiological actions of the selective sigma receptor ligand (+)-pentazocine, Neuropsychopharmacology. 4:321– 327.Google Scholar
  28. Su, T.-P., 1982, Evidence for sigma opioid receptor: binding of [3H] SKF-10,047 to etorphine-inaccesible sites in guinea pig brain, J. Pharmacol. Exper. Ther., 223:284–290.Google Scholar
  29. Su, T.-P., London, E.D. and Jaffe, J.H., 1988, Steroid binding at sigma receptors suggests a link between endocrine, nervous and immune systems, Science, 240:219–221.PubMedCrossRefGoogle Scholar
  30. Tam, S.W. and Cook, L., 1984, Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H] haloperidol binding in guinea pig brain membranes, Proc. Natl. Acad. Sci. U.S.A., 80:5618–5621.CrossRefGoogle Scholar
  31. Taylor, D.P. and Dekleva, J., 1987, Potential antipsychotic BMY 14802 selectively binds to sigma sites, Drug. Dev. Res., 11:65–70.CrossRefGoogle Scholar
  32. Taylor, D.P., Eison, M.S., Moon, S.L. and Yoccam F.D., 1989, BMY 14802: a potential antipsychotic with selective affinity for sigma binding sites, in: “Schizophrenia,” C.A. Tamminga and S.C. Schulz, eds., Advances in Neuropsychiatry, vol. 1, Raven Press, New York.Google Scholar
  33. Tortella, F.C. and Musacchio, J.M., 1986, Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties, Brain Res., 383:314–318.PubMedCrossRefGoogle Scholar
  34. Vaupel, D.B. and Su, T.-P., 1987, Guinea pig vas deferens may contain both sigma receptors and phencyclidine receptors, Eur. J. Pharmacol., 139:125–128.PubMedCrossRefGoogle Scholar
  35. Wachtel, S.R. and White, F.J., 1988, Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies, J. Pharmacol. Exper. Ther., 244:410–416.Google Scholar
  36. Weber, E., Sonders, M., Quarum, M., McLean, S., Pou, S. and Keana, J.F.W., 1986, 1,3-Di(2-[5-3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs, Proc. Natl. Acad. Sci. U.S.A., 83:8784–8788.PubMedCrossRefGoogle Scholar
  37. Wolfe, S.A., Jr., Culp, S.G. and De Souza, E.B., 1989, Sigma receptors in endocrine organs: identification, characterization and autoradiographic localization in rat pituitary, adrenal, testis and ovary, Endocrinology, 124:1160–1172.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • E. W. Karbon
    • 1
  • S. J. Enna
    • 1
  1. 1.Nova Pharmaceutical CorporationBaltimoreUSA

Personalised recommendations